254 related articles for article (PubMed ID: 27786239)
1. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
Reddy TL; Garikapati KR; Reddy SG; Reddy BV; Yadav JS; Bhadra U; Bhadra MP
Sci Rep; 2016 Oct; 6():35223. PubMed ID: 27786239
[TBL] [Abstract][Full Text] [Related]
2. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
[TBL] [Abstract][Full Text] [Related]
3. Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes.
Moku G; Gulla SK; Nimmu NV; Khalid S; Chaudhuri A
Biomater Sci; 2016 Apr; 4(4):627-38. PubMed ID: 26806172
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells.
Wang Y; Zhou L; Xiao M; Sun ZL; Zhang CY
Colloids Surf B Biointerfaces; 2017 Jan; 149():16-22. PubMed ID: 27716527
[TBL] [Abstract][Full Text] [Related]
5. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
6. Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer.
Büyükköroğlu G; Şenel B; Başaran E; Yenilmez E; Yazan Y
Eur J Pharm Biopharm; 2016 Dec; 109():174-183. PubMed ID: 27793757
[TBL] [Abstract][Full Text] [Related]
7. Co-Delivery of Paclitaxel and shMCL-1 by Folic Acid-Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance.
Nie W; Wang B; Mi X; Chen J; Yu T; Miao J; Lin Y; Yang T; Ran M; Hong Z; Liu X; Liang X; Qian Z; Gao X
Small Methods; 2021 May; 5(5):e2001132. PubMed ID: 34928100
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
[TBL] [Abstract][Full Text] [Related]
9. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
10. Liposomal co-delivery of curcumin and albumin/paclitaxel nanoparticle for enhanced synergistic antitumor efficacy.
Ruttala HB; Ko YT
Colloids Surf B Biointerfaces; 2015 Apr; 128():419-426. PubMed ID: 25797481
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
12. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
13. Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier.
Hu Y; Liu N; Cheng B; Tan Y; Wen L; Yuan H; Hu F
Oncotarget; 2016 Dec; 7(50):83258-83269. PubMed ID: 27825127
[TBL] [Abstract][Full Text] [Related]
14. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Xiao Y; Wang S; Zong Q; Yin Z
AAPS PharmSciTech; 2018 Jul; 19(5):2395-2406. PubMed ID: 29869309
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
17. A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Chen M; Song F; Liu Y; Tian J; Liu C; Li R; Zhang Q
Nanoscale; 2019 Mar; 11(9):3814-3826. PubMed ID: 30600823
[TBL] [Abstract][Full Text] [Related]
18. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
19. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer.
Du J; Shao Y; Hu Y; Chen Y; Cang J; Chen X; Pei W; Miao F; Shen Y; Muddassir M; Zhang Y; Zhang J; Teng G
ACS Appl Mater Interfaces; 2021 May; 13(20):23396-23409. PubMed ID: 33982563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
